Abstract
Obesity is a chronic and relapsing disease marked by excessive fat accumulation that poses serious health risks, with an increasing global prevalence including in low- and middle-income countries. Obesity-related complications, including cardiovascular diseases, diabetes, and cancer, also contribute to significant healthcare costs. Management strategies involve lifestyle modifications, pharmacological interventions, and, in severe cases, surgical procedures. Semaglutide, a GLP-1 receptor agonist, has emerged as an effective treatment for both obesity and type 2 diabetes, showing significant weight loss outcomes and improvements in metabolic health across various patient groups. However, careful monitoring of adverse effects and drug interactions is crucial for optimizing therapeutic outcomes.Several novel agents are under development, with multi-hormone receptor agonists and oral formulations likely to become available in the coming years. As effective treatment options expand, cost and availability will need to be addressed to enable equitable access to treatment. Bangladesh J Medicine 2024; 35: 133-146
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
